Mr. Stone leads City of Hope, one of the nation’s largest and most advanced cancer research and treatment organizations, where he has advanced a vision to connect lifesaving innovation to the patients and communities who need it most. His efforts have driven financial performance that surged more than 70% over the past two years through disciplined operational integration, strategic service-line growth and one of the strongest philanthropic engines in cancer care. Under his leadership, City of Hope launched a national clinical trials network in 2025 that enables simultaneous trial activation across multiple states, accelerating access to investigational therapies for patients who historically lacked such opportunities. Under his leadership, the system also opened Orange County’s first specialty cancer hospital and unveiled the system’s largest outpatient cancer center, Hope Plaza in Los Angeles, to bring complex care including CAR T-cell therapy into community settings. Mr. Stone has guided City of Hope to become a global leader in immunotherapy, CAR T-cell therapy, stem cell transplantation and precision medicine, with a translational infrastructure that includes two on-campus Good Manufacturing Practice facilities and now impacts more than 200 million people worldwide. His policy leadership has been equally consequential, including: founding AccessHope to extend National Cancer Institute-designated cancer center expertise virtually to communities across the country, now impacting more than 9 million lives; championing the California Cancer Care Equity Act to expand precision medicine and clinical trial access for approximately 15 million Medi-Cal patients; and leading the “Cancer Care is Different” coalition to widen insurance networks for vulnerable populations. The organization’s employee engagement is near the national 90th percentile and boasts a turnover rate of 10.5% compared to a 15.1% national average. Mr. Stone has been named “Hospital CEO of the Year” by the Los Angeles Business Journal and included among the “100 Most Influential CEOs in Oncology” by OncoDaily.
